Cargando…

Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells

Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and proliferation of pulmonary arterial smooth muscle cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatfield, John, Mueller Grandjean, Celia, Sasse, Thomas, Clozel, Martine, Nayler, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471877/ https://www.ncbi.nlm.nih.gov/pubmed/23077657 http://dx.doi.org/10.1371/journal.pone.0047662

Ejemplares similares

Distinct ET(A) Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis
por: Gatfield, John, et al.
Publicado: (2014)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection
por: Landázuri, Natalia, et al.
Publicado: (2021)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Efficacy and safety of the endothelin-1 receptor antagonist macitentan in epicardial and microvascular vasospasm; a proof-of-concept study
por: Feenstra, Rutger G.T., et al.
Publicado: (2023)

Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ET(A) Versus ET(B) Receptors and on the Functionality of Endothelial ET(B) Receptors
por: Iglarz, Marc, et al.
Publicado: (2015)

Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P(1) Receptor Modulator
por: Rey, Markus, et al.
Publicado: (2013)

Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia
por: Maffei, Rossana, et al.
Publicado: (2017)

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
por: Lepist, Eve-Irene, et al.
Publicado: (2014)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern
por: Treiber, Alexander, et al.
Publicado: (2020)

The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation
por: Steven, Sebastian, et al.
Publicado: (2018)

Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma
por: Muñoz-Garcia, Javier, et al.
Publicado: (2022)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)

Iontophoresis of Endothelin Receptor Antagonists in Rats and Men
por: Roustit, Matthieu, et al.
Publicado: (2012)

Evidence for biased agonists and antagonists at the endothelin receptors
por: Maguire, Janet J.
Publicado: (2016)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
por: Droste, Annette S, et al.
Publicado: (2009)

Beyond Vasodilator: Anti-Apoptotic Effect of Endothelin Receptor Antagonist
por: Chang, Sung-A
Publicado: (2014)

Clinical and hemodynamic effect of endothelin receptor antagonists in Eisenmenger Syndrome
por: Yonas, Emir, et al.
Publicado: (2020)

Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor
por: Montgomery, Jennifer P, et al.
Publicado: (2008)

Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells
por: Peduto Eberl, L, et al.
Publicado: (2003)

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
por: Steiner, M Kathryn, et al.
Publicado: (2008)

Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy
por: Enevoldsen, Frederik C., et al.
Publicado: (2020)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis
por: Arefiev, Kait, et al.
Publicado: (2011)

Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
por: Badagliacca, Roberto, et al.
Publicado: (2020)

Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?
por: Javor, S., et al.
Publicado: (2020)

Clinicians' preferences for managing aneurysmal subarachnoid hemorrhage using endothelin receptor antagonists
por: Heidenreich, Sebastian, et al.
Publicado: (2023)

A non-selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow-derived cells in ameliorating pulmonary hypertension in mice
por: Kato, Taichi, et al.
Publicado: (2020)

Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics
por: Hothersall, J. Daniel, et al.
Publicado: (2017)

Role of ERK/MAPK in endothelin receptor signaling in human aortic smooth muscle cells
por: Chen, Qing-wen, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mt8farh9peah597vl2mqfnjcc7